文献速递疼痛医学

口服富马酸二甲酯通过NFE2L2抗氧化信号减轻啮齿类动物周围神经病理性疼痛

Oral Dimethyl Fumarate Reduces Peripheral Neuropathic Pain in Rodents via NFE2L2 Antioxidant Signaling.
PubMed 文献 · Anesthesiology · 2020-01-01

该研究在大鼠和小鼠神经损伤模型中测试口服富马酸二甲酯,发现其可逆转机械性异常性疼痛和痛觉过敏,且该效应依赖NFE2L2,同时改善氧化应激、神经炎症和线粒体功能。

要点

  • 富马酸二甲酯逆转神经损伤诱发的机械性异常性疼痛和痛觉过敏。
  • 镇痛效应依赖NFE2L2,Nfe2l2缺失小鼠中丢失。
  • 富马酸二甲酯增强超氧化物歧化酶活性、降低炎性因子并恢复线粒体功能。

核心结论

  • 口服富马酸二甲酯通过激活NFE2L2抗氧化信号减轻周围神经损伤诱导的痛觉超敏。
  • 富马酸二甲酯改善神经炎症和线粒体功能障碍等氧化应激依赖机制。

研究设计与样本

  • 雄性Sprague Dawley大鼠及雄性和雌性野生型与Nfe2l2小鼠,神经损伤或假手术后口服富马酸二甲酯或溶媒5天(300 mg/kg,每日),每组n=5至8。

主要发现

  • 富马酸二甲酯逆转机械性异常性疼痛:损伤+溶媒组0.45 ± 0.06 g,损伤+富马酸二甲酯组8.2 ± 0.16 g,P < 0.001。
  • 富马酸二甲酯逆转痛觉过敏:损伤+溶媒组6次中有2次跨越有害探针,损伤+富马酸二甲酯组6次中有6次跨越,P = 0.013。
  • 抗异常性疼痛效应在Nfe2l2小鼠中丢失,在野生型中保留:野生型0.94 ± 0.25 g,Nfe2l2 0.02 ± 0.01 g,P < 0.001。
  • 富马酸二甲酯增加超氧化物歧化酶活性:损伤+溶媒组3.96 ± 1.28 mU/mg,损伤+富马酸二甲酯组7.97 ± 0.47 mU/mg,P < 0.001。
  • 富马酸二甲酯降低白细胞介素-1β:损伤+溶媒组13.30 ± 2.95 pg/mg,损伤+富马酸二甲酯组6.33 ± 1.97 pg/mg,P = 0.022;并恢复基础呼吸容量(P = 0.025)。

临床怎么用

  • 富马酸二甲酯作为非阿片类口服药物,可能为周围神经病理性疼痛提供新治疗选择,但需临床研究验证。

局限性

  • 研究为啮齿类动物模型,结果尚不能直接外推至人类。
  • 样本量较小(每组n=5至8),需更大规模研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Available treatments for neuropathic pain have modest efficacy and significant adverse effects, including abuse potential. Because oxidative stress is a key mechanistic node for neuropathic pain, the authors focused on the master regulator of the antioxidant response-nuclear factor erythroid 2-related factor 2 (NFE2L2; Nrf2)-as an alternative target for neuropathic pain. The authors tested whether dimethyl fumarate (U.S. Food and Drug Administration-approved treatment for multiple sclerosis) would activate NFE2L2 and promote antioxidant activity to reverse neuropathic pain behaviors and oxidative stress-dependent mechanisms. METHODS: Male Sprague Dawley rats, and male and female wild type and Nfe2l2 mice were treated with oral dimethyl fumarate/vehicle for 5 days (300 mg/kg; daily) after spared nerve injury/sham surgery (n = 5 to 8 per group). Allodynia was measured in von Frey reflex tests and hyperalgesia in operant conflict-avoidance tests. Ipsilateral L4/5 dorsal root ganglia were assayed for antioxidant and cytokine/chemokine levels, and mitochondrial bioenergetic capacity. RESULTS: Dimethyl fumarate treatment reversed mechanical allodynia (injury-vehicle, 0.45 ± 0.06 g [mean ± SD]; injury-dimethyl fumarate, 8.2 ± 0.16 g; P < 0.001) and hyperalgesia induced by nerve injury (injury-vehicle, 2 of 6 crossed noxious probes; injury-dimethyl fumarate, 6 of 6 crossed; P = 0.013). The antiallodynic effect of dimethyl fumarate was lost in nerve-injured Nfe2l2 mice, but retained in nerve-injured male and female wild type mice (wild type, 0.94 ± 0.25 g; Nfe2l2, 0.02 ± 0.01 g; P < 0.001). Superoxide dismutase activity was increased by dimethyl fumarate after nerve injury (injury-vehicle, 3.96 ± 1.28 mU/mg; injury-dimethyl fumarate, 7.97 ± 0.47 mU/mg; P < 0.001). Treatment reduced the injury-dependent increases in cytokines and chemokines, including interleukin-1β (injury-vehicle, 13.30 ± 2.95 pg/mg; injury-dimethyl fumarate, 6.33 ± 1.97 pg/mg; P = 0.022). Injury-impaired mitochondrial bioenergetics, including basal respiratory capacity, were restored by dimethyl fumarate treatment (P = 0.025). CONCLUSIONS: Dimethyl fumarate, a nonopioid and orally-bioavailable drug, alleviated nociceptive hypersensitivity induced by peripheral nerve injury via activation of NFE2L2 antioxidant signaling. Dimethyl fumarate also resolved neuroinflammation and mitochondrial dysfunction-oxidative stress-dependent mechanisms that drive nociceptive hypersensitivity after nerve injury.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Li J, Ma J, Lacagnina MJ, et al. Oral Dimethyl Fumarate Reduces Peripheral Neuropathic Pain in Rodents via NFE2L2 Antioxidant Signaling. Anesthesiology. 2020. PMID: 31939850. doi:10.1097/ALN.0000000000003077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。